GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report)’s share price traded up 8.8% during trading on Wednesday. The company traded as high as $51.35 and last traded at $51.4450. Approximately 529,900 shares changed hands during mid-day trading, a decline of 44% from the average daily volume of 943,280 shares. The stock had previously closed at $47.29.
Analyst Ratings Changes
Several equities analysts recently commented on WGS shares. Zacks Research raised shares of GeneDx from a “hold” rating to a “strong-buy” rating in a research note on Monday. Wall Street Zen upgraded GeneDx from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings reissued a “sell (d)” rating on shares of GeneDx in a report on Monday, November 2nd. Canaccord Genuity Group boosted their price target on shares of GeneDx from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Finally, BTIG Research reissued a “buy” rating and set a $85.00 price objective on shares of GeneDx in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $90.14.
Check Out Our Latest Stock Report on GeneDx
GeneDx Stock Performance
The firm has a market cap of $1.36 billion, a P/E ratio of -12.03 and a beta of 2.00. The business has a fifty day simple moving average of $70.97 and a 200-day simple moving average of $69.25. The company has a quick ratio of 3.85, a current ratio of 4.16 and a debt-to-equity ratio of 0.60.
GeneDx (NASDAQ:WGS – Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.07 by $0.21. The business had revenue of $123.10 million for the quarter, compared to analysts’ expectations of $122.93 million. GeneDx had a negative net margin of 24.10% and a positive return on equity of 1.98%. During the same quarter in the prior year, the company earned ($0.27) earnings per share. On average, sell-side analysts predict that GeneDx Holdings Corp. will post -0.37 EPS for the current fiscal year.
Insider Transactions at GeneDx
In related news, CEO Katherine Stueland sold 10,501 shares of the stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $97.61, for a total transaction of $1,025,002.61. Following the sale, the chief executive officer directly owned 115,476 shares of the company’s stock, valued at approximately $11,271,612.36. This represents a 8.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Kevin Feeley sold 3,728 shares of the stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $97.61, for a total transaction of $363,890.08. Following the sale, the chief financial officer owned 44,945 shares in the company, valued at approximately $4,387,081.45. The trade was a 7.66% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 19,206 shares of company stock worth $1,808,056. 25.17% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On GeneDx
Large investors have recently added to or reduced their stakes in the stock. First Light Asset Management LLC grew its stake in shares of GeneDx by 222.7% during the 2nd quarter. First Light Asset Management LLC now owns 783,923 shares of the company’s stock valued at $53,816,000 after purchasing an additional 540,996 shares during the period. Bank of America Corp DE lifted its holdings in GeneDx by 77.5% during the first quarter. Bank of America Corp DE now owns 234,606 shares of the company’s stock valued at $15,066,000 after purchasing an additional 102,456 shares in the last quarter. Lazard Asset Management LLC bought a new stake in shares of GeneDx during the 1st quarter valued at $2,177,000. Bank of New York Mellon Corp bought a new stake in shares of GeneDx during the 2nd quarter valued at $4,258,000. Finally, Assenagon Asset Management S.A. lifted its stake in shares of GeneDx by 108.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 632,413 shares of the company’s stock valued at $45,723,000 after buying an additional 328,980 shares in the last quarter. Institutional investors own 61.72% of the company’s stock.
About GeneDx
GeneDx is a genomic testing company focused on helping clinicians diagnose rare and inherited conditions. Its services include whole exome and whole genome sequencing, along with other genetic tests and clinical interpretation of results. The company’s testing is used by healthcare providers to support diagnosis and care decisions, particularly for patients with suspected rare genetic disorders. GeneDx also offers testing related to hereditary cancer risk. Founded in 2000 by researchers with experience at the National Institutes of Health, GeneDx has developed its business around applying genomic information in clinical care.
Further Reading
- Five stocks we like better than GeneDx
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
- Cracks in the Crockery? Williams-Sonoma Insiders Sell Shares
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.
